Dr. Yazeed Sawalha
Claim this profileOhio State University Comprehensive Cancer Center
Studies Cancer
Studies Non-Hodgkin's Lymphoma
4 reported clinical trials
10 drugs studied
Area of expertise
1Cancer
MYC positive
BCL2 positive
BCL6 positive
2Non-Hodgkin's Lymphoma
MYC positive
BCL2 positive
BCL6 positive
Affiliated Hospitals
Clinical Trials Yazeed Sawalha is currently running
Epcoritamab + Ibrutinib
for Non-Hodgkin's Lymphoma
This phase Ib/II trial evaluates the safety, optimal dose, and efficacy of the combination of epcoritamab and ibrutinib in treating patients with aggressive B-cell non-Hodgkin lymphoma that has come back (relapsed) or responded to previous treatment (refractory). Epcoritamab, a bispecific antibody, binds to two different types of receptors (proteins present on the cell surface) at the same time. The two receptors that epcoritamab binds to are called CD3 and CD20. CD3 is found on T cells, which are important cells of the immune system that help fight cancer and infections. CD20 is found on the surface of most types of aggressive B-cell non-Hodgkin lymphoma cells. By binding to both CD3 and CD20, epcoritamab brings the two cells close together so the T cells can fight and kill the lymphoma B cells. Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, binds to a protein on B cells, a type of white blood cell from which the lymphoma developed. By doing this it decreases the ability of the lymphoma B cells to survive and grow. Ibrutinib may also improve the health (or fitness) of T cells thus making epcoritamab safer and/or more effective.
Recruiting1 award Phase 1 & 25 criteria
Rituximab vs Mosunetuzumab
for Follicular Lymphoma
This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. It is not yet known if giving rituximab or mosunetuzumab works better in treating patients with follicular lymphoma with a low tumor burden.
Recruiting2 awards Phase 313 criteria
More about Yazeed Sawalha
Clinical Trial Related1 year of experience running clinical trials · Led 4 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Yazeed Sawalha has experience with
- Rituximab
- Cyclophosphamide
- Prednisone
- Vincristine Sulfate
- Epcoritamab
- Ibrutinib
Breakdown of trials Yazeed Sawalha has run
Cancer
Non-Hodgkin's Lymphoma
Follicular Lymphoma
Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Yazeed Sawalha specialize in?
Yazeed Sawalha focuses on Cancer and Non-Hodgkin's Lymphoma. In particular, much of their work with Cancer has involved MYC positive patients, or patients who are BCL2 positive.
Is Yazeed Sawalha currently recruiting for clinical trials?
Yes, Yazeed Sawalha is currently recruiting for 3 clinical trials in Columbus Ohio. If you're interested in participating, you should apply.
Are there any treatments that Yazeed Sawalha has studied deeply?
Yes, Yazeed Sawalha has studied treatments such as Rituximab, Cyclophosphamide, Prednisone.
What is the best way to schedule an appointment with Yazeed Sawalha?
Apply for one of the trials that Yazeed Sawalha is conducting.
What is the office address of Yazeed Sawalha?
The office of Yazeed Sawalha is located at: Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210 United States. This is the address for their practice at the Ohio State University Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.